EXEL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Exelixis provided an update on the Phase 3 STELLAR-303 trial of zanzalintinib combined with an immune checkpoint inhibitor in metastatic colorectal cancerJun 22, 2026
- Exelixis and Merck enter clinical development collaboration for Phase 3 STELLAR-316 colorectal cancer trialMay 19, 2026
- FDA accepted Exelixis' NDA for zanzalintinib combination in metastatic colorectal cancerFeb 2, 2026
- Exelixis' partner Ipsen receives European Commission approval for CABOMETYX® (cabozantinib) for patients with previously treated advanced neuroendocrine tumorsJul 25, 2025
- Exelixis' partner Ipsen receives positive CHMP opinion for CABOMETYX® (cabozantinib) in previously treated advanced neuroendocrine tumorsJun 20, 2025